<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259831</url>
  </required_header>
  <id_info>
    <org_study_id>CVT-E002-2005-3</org_study_id>
    <nct_id>NCT00259831</nct_id>
  </id_info>
  <brief_title>Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults</brief_title>
  <official_title>Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adult Employees in Continuing Care Facilities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CV Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Capital Health, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Afexa Life Sciences Inc</source>
  <brief_summary>
    <textblock>
      The purpose of the Study is to determine the prophylactic effects of CVT-E002 treatment for&#xD;
      upper respiratory tract infections in healthy adult employees working with residents in&#xD;
      continuing care facilities. It is hypothesized that the use of CVT-E002 will effectively&#xD;
      reduce the incidence, severity and duration of upper respiratory infections among the&#xD;
      participants when compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible continuing care employees will be randomly assigned to either the treatment or&#xD;
      placebo group with equal numbers in each group. The treatment will consist of taking two&#xD;
      capsules of CVT-E002 (400mg)or placebo every morning, after breakfast, for a period of 12&#xD;
      weeks. The subjects will be given an assessment form to log specific symptoms on a daily&#xD;
      basis if they get a cold.&#xD;
&#xD;
      Symptoms include sore throat, runny nose, nasal congestion, hoarseness, cough, earaches, and&#xD;
      fever. Subjects will be required to maintain the same dosing even during an upper respiratory&#xD;
      infection and will be requested not to take any additional medication for their upper&#xD;
      respiratory infection unless prescribed by their family physicians.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the efficacy of CVT-E002 in reducing the number of upper respiratory infections during the study.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To test if the prophylactic management with CVT-E002 decreases the severity and duration of symptoms related to an upper respiratory tract infection.</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Upper Respiratory Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVT-E002 (Cold-FX); a natural health product</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-64 years&#xD;
&#xD;
          -  not pregnant or breast feeding&#xD;
&#xD;
          -  good general health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  medical conditions: HIV infection; malignancy; cardiovascular disease; hypertension;&#xD;
             renal, pulmonary or hepatic abnormalities; neurologic or psychiatric disease;&#xD;
             tuberculosis; multiple sclerosis; recent acute respiratory infection (&lt;2 weeks)&#xD;
&#xD;
          -  medications: warfarin; immunosuppressive therapy; corticosteroids; phenalzine;&#xD;
             pentobarbital; haloperidol&#xD;
&#xD;
          -  major surgical procedure in the previous six months&#xD;
&#xD;
          -  history of alcohol/drug abuse&#xD;
&#xD;
          -  pregnancy and lactation in women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerry Predy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital Health, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Capital Care Group Continuing Care facilities</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 2J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>November 29, 2005</study_first_submitted>
  <study_first_submitted_qc>November 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2005</study_first_posted>
  <last_update_submitted>June 4, 2009</last_update_submitted>
  <last_update_submitted_qc>June 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2009</last_update_posted>
  <keyword>cold</keyword>
  <keyword>influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

